GlassScriptPhysician profile
Michael Raciti
NPI 1780812537
$5,610.62
in general payments reported to CMS, 2019-2025
32 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $208 · 2021: $255 · 2022: $899 · 2023: $662 · 2024: $1,419 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,237 · Education: $99.99 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,236.63 |
| Education | $99.99 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,281.42 | 2019-2025 | Clareon, Hydrus Microstent, Ngenuity |
| Sight Sciences, INC. | $461.01 | 2019-2024 | Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $425.79 | 2019-2025 | Eylea Hd, Eylea |
| Glaukos Corporation | $411.21 | 2019-2024 | Idose, Radius, Istent Trabecular Micro-Bypass System Model Is3 |
| Astellas Pharma US INC | $378.39 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $331.34 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $251.33 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $228.72 | 2024-2025 | Acthar |
| Oyster Point Pharma, INC. | $211.30 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $200.39 | 2019-2023 | |
| Apellis Pharmaceuticals, INC. | $179.10 | 2023-2025 | Syfovre |
| Rxsight INC | $176.22 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Rayner Intraocular Lenses Limited | $169.23 | 2022-2024 | Omidria, Rayone Spheric, Rayone Emv |
| Allergan, INC. | $154.76 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $108.64 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $88.86 | 2023-2024 | Streamline, Ahmed Glaucoma Valve, Clearpath |
| Thea Pharma INC. | $74.42 | 2023-2025 | Iyuzeh |
| Biotissue Holdings INC. | $63.27 | 2021-2025 | |
| Horizon Therapeutics Plc | $54.23 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $53.58 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $44.40 | 2024-2025 | Xdemvy |
| Omeros Corporation | $40.74 | 2019 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Amgen INC. | $36.13 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $31.80 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $24.76 | 2024 | Tecnis Simplicity |
| Harrow Eye, LLC | $18.87 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $17.90 | 2019 | |
| Genentech USA, INC. | $16.07 | 2025 | Vabysmo |
| Ocular Therapeutix, INC. | $14.21 | 2023 | Dextenza |
| Lumibird Medical INC. | $14.00 | 2021 | |
| The Cameron-Ehlen Group, INC. | $9.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Raciti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.